Paul A. Bunn, Jr., MD is among the world's leading thoracic oncologists, currently serving as Distinguished Professor at the University of Colorado Cancer Center and James Dudley Professor of Lung Cancer Research at the University of Colorado School of Medicine. He was named “2016 David A. Karnofsky Memorial Award and Lecture recipient”, the most prestigious award of the American Society of Clinical Oncology's (ASCO). Among his leadership roles, Dr. Bunn is the former President of ASCO, former Chair of the ASCO Foundation Board, former President of the IASLC, former President of the AACI, former Director or the Univ. of Colorado Comprehensive Cancer Center and former Executive Director of the IASLC. Dr. Bunn also served as the Chairman of the Oncology Drug Advisory Committee of the U.S. FDA. Dr. Bunn is the Chair of the Lung Cancer Mutation Consortium.
Weiping Zou, MD, PhD is a leading scientist in cancer immunology well-noted for his work driving the understanding of the nature of human tumor immune responses in the cancer microenvironment and developing mechanism-informed combination therapies for cancer. Dr. Zou is the Charles B. de Nancrede Professor of Pathology, Immunology, Biology, and Surgery at the University of Michigan. He serves as Director of Center of Excellence for Cancer Immunology and Immunotherapy, and Co-Director of the Cancer Hematopoiesis and Immunology Program and Immunologic Monitoring Core at the University of Michigan Rogel Cancer Center. Among his leadership positions, Dr. Zou is currently the American Association for Cancer Research (AACR) Cancer Immunology (CIMM) Chairperson. Dr. Zou's laboratory has delivered many cutting-edge scientific discoveries and is one of the most cited research teams in the field of immunology.
Richard S. Finn, MD is a leading expert in cancer drug development and liver cancer. He has played a pivotal role in the development of the first CDK4/6 inhibitor palbociclib (Ibrance). Dr. Finn is a Professor of Clinical Medicine in the Hematology/Oncology Division at the David Geffen School of Medicine, and the Director of the Signal Transduction Program in the Jonsson Comprehensive Cancer Center at UCLA. He is the former President of the International Liver Cancer Association, current senior editor of Clinical Cancer Research and Breast Cancer Research, and on the editorial boards of Journal of Hepatology, and Liver Cancer. While dedicating his research to developing molecularly targeted agents and identifying predictive markers of response to novel cancer drugs, Dr. Finn has also served as principal and sub-investigator in clinical trials for targeted and immune-therapies against breast and hepatocellular carcinoma.